<DOC>
	<DOCNO>NCT01194635</DOCNO>
	<brief_summary>RATIONALE : Studying sample blood tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor understand patient respond treatment . PURPOSE : This research study study biomarkers response blood tumor tissue sample patient unresectable stage IV squamous cell carcinoma head neck previously treat cetuximab , cisplatin , radiation therapy .</brief_summary>
	<brief_title>Biomarkers Response Blood Tumor Tissue Samples From Patients With Unresectable Stage IV Squamous Cell Cancer Head Neck Previously Treated With Cetuximab , Cisplatin , Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To expand upon list molecular correlate indicate clinical trial ECOG-E3303 , include EGFR expression , EGFR phosphorylation , map kinase , AKT , STAT3 . - To correlate status expression level biomarker clinical outcome ( response , progression-free survival , overall survival ) . OUTLINE : Archived tumor blood specimen analyze human papilloma virus p16 status ; EGFR gene amplification ; level ERCC1 , XPF , c-Met protein ; expression activation several signal pathway include PI3 kinase gene mTOR ; level ErbB2 , ErbB3 , P70S6 kinase , S6 , Akt ; expression amphiregulin ( AR ) , TGF-alpha ( TGF-Î± ) , heparin-binding EGF-like growth factor ( HB-EGF ) , EGF , epiregulin c-Met ligand , hepatocyte growth factor fluorescence situ hybridization ( FISH ) , automate situ quantitative measurement protein analysis ( AQUA ) , IHC , PCR , ELISA .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis squamous cell carcinoma head neck Stage IV disease Unresectable disease Treated cetuximab , cisplatin , radiotherapy clinical trial ECOGE3303 Archived blood tumor tissue sample available PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
</DOC>